Diabetes drug tirzepatide may revolutionize alcohol addiction treatment

A drug originally developed for diabetes could soon offer a new way to treat alcohol dependence. Tirzepatide, the active ingredient in Mounjaro, has shown striking results in animal studies, cutting alcohol intake by more than half. Researchers now believe it may also reshape the brain's response to addiction over time.

Scientists at the University of Gothenburg discovered that tirzepatide significantly reduces alcohol consumption in lab animals. The drug not only lowered intake by over 50% but also reduced the likelihood of relapse. Unlike existing treatments, it works by targeting two key receptors—GIP and GLP-1—rather than just one.

Tirzepatide's effect goes beyond short-term suppression. Studies suggest it triggers epigenetic changes in the brain, potentially creating lasting shifts in addictive behaviour. The drug also alters the dopamine reward system, weakening the brain's response to alcohol.

Despite these promising findings, no formal trials for alcohol dependence have yet been submitted to regulators like the EMA or FDA as of early 2026. However, its existing approval for diabetes might speed up future reviews. Further human studies will be required before it can be officially repurposed for addiction treatment.

Tirzepatide presents a novel approach to tackling alcohol dependence, combining immediate reductions in drinking with possible long-term brain changes. While still in early stages, its dual-action mechanism sets it apart from current medications. Approval for this new use will depend on upcoming clinical trials and regulatory assessments.